Cancer Neuropathic Pain: Overview of Current Status and Future Objectives

Disclosures: Frederick H. Hausheer: Employment/leadership position: BioNumerik Pharmaceuticals, Inc., KI Pharmaceuticals, Inc.; Intellectual property rights/inventor/patent holder: BioNumerik Pharmaceuticals, Inc.; Ownership interest: BioNumerik Pharmaceuticals, Inc.; Kathleen M. Foley: Consultant/advisory role: NCCN, NCIBCA. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.